Skip to content
2000
Volume 17, Issue 9
  • ISSN: 1389-2010
  • E-ISSN: 1873-4316

Abstract

During drug development, large libraries of new chemical entities (NCEs) are generated and undergo in vitro screens of metabolism and cytotoxicity. These screens are heavily relied upon to select lead compounds with the highest chance of success in pre-clinical studies and clinical trials, but suffer from limited in vivo predictive power despite using human liver-derived components. There is a need for new assays that utilize smaller reagent volumes to reduce the cost of these high-throughput screens; better mimic the liver environment; and ultimately account for toxicities in other major organ systems. Microfabricated devices, in their current state, integrate multiple reaction steps in a single device, decreasing the cost of a single metabolism or cytotoxicity screen by lowering the reagent consumption and increasing throughput. The incorporation of three-dimensional co-cultures in these devices promise increased accuracy of in vitro screens, because cellular phenotype and response of hepatocytes in these cultures are more representative of the liver. In this review, we focus on microfabricated devices developed over the past decade and highlight technologies that we believe have the potential of reaching shorter- and longer-term goals of reducing the cost of bringing new drugs to market and revolutionizing the discovery stage of the drug development pipeline.

Loading

Article metrics loading...

/content/journals/cpb/10.2174/1389201017666160301103648
2016-07-01
2025-09-15
Loading full text...

Full text loading...

/content/journals/cpb/10.2174/1389201017666160301103648
Loading
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test